Frameless stereotaxy in subthalamic deep brain stimulation: 3-year clinical outcome.
BACKGROUND
In most centers, the surgery of deep brain stimulation (DBS) is performed using a stereotactic frame. Compared with frame-based technique, frameless stereotaxy reduces the duration of surgical procedure and patient's discomfort, with lead placing accuracy equivalent after the learning curve. Although several studies have investigated the targeting accuracy of this technique, only a few studies reported clinical outcomes, with data of short-term follow-up.


OBJECTIVE
To assess clinical efficacy and safety of frameless bilateral subthalamic nucleus (STN) DBS in Parkinson's disease (PD) patients at 1- and 3-year follow-up.


METHODS
Consecutive PD patients who underwent bilateral STN-DBS with a manual adjustable frameless system were included in the study. The data were collected retrospectively.


RESULTS
Eighteen PD patients underwent bilateral STN-DBS implant and were included in the study. All patients completed 1-year observation and ten of them completed 3-year observation. At 1-year follow-up, motor efficacy of STN stimulation in off-med condition was of 30.1% (P = 0.003) and at 3-year follow-up was of 36.3%, compared with off-stim condition at 3-year follow-up (P = 0.005). Dopaminergic drugs were significantly reduced by 31.2% 1 year after the intervention (P = 0.003) and 31.7% 3 years after the intervention (P = 0.04). No serious adverse events occurred during surgery.


CONCLUSIONS
Frameless stereotaxy is an effective and safe technique for DBS surgery at 1- and 3-year follow-up, with great advantages for patients' discomfort during surgery.
['Piano|Carla|C|', 'Bove|Francesco|F|https://orcid.org/0000-0002-2959-6659', 'Mulas|Delia|D|', 'Bentivoglio|Anna Rita|AR|', 'Cioni|Beatrice|B|', 'Tufo|Tommaso|T|']
D046690:Deep Brain Stimulation D006801:Humans D038361:Neuronavigation D010300:Parkinson Disease D012189:Retrospective Studies D020531:Subthalamic Nucleus D016896:Treatment Outcome
Frameless Deep brain stimulation Subthalamic nucleus Parkinson’s disease Personalized medicine